"...an essential multi-authored book (136 authors), edited by two individuals with a large and particularly well-recognized expertise in all 'proteomic fields'...Such an impressive overview of most of the relevant characteristics of clinical proteomics, the quality (as well as the homogeneity) of the texts, the generally beautiful pictures illustrating the different chapters make the book an important source of information for everybody interested in clinical proteomics as well as in translational medicine." BIOTECHNOLOGY Unparalleled in its scope and depth, this book brings together proteomic approaches use in the discovery and development of diagnostic and prognostic biomarkers that are applicable to all clinical fields. Following an overview of state-of-the-art technologies and strategies currently being applied to clinical proteomics, the book focuses on individual diseases including cancer, diabetes, stroke and cardiopulmonary, renal and autoimmune diseases as well as clinical toxicology finishing with a discussion of the future of clinical proteomics. This new discipline in molecular medicine holds promise to revolutionize the practice of medicine and this book is a first.
Jennifer Van Eyk is the Director of the Johns Hopkins Bayview Proteomics Center and Professor of Medicine, Biological Chemistry and Biomedical Engineering at Johns Hopkins University in Baltimore, Maryland. She has developed novel methods to investigate heart disease including preconditioning, ischemic injury and heart failure with emphasis on both understanding the underlying pathological mechanism and for the development of diagnostic biomarkers. Dr. Van Eyk sits on numerous editorial boards including Proteomics, Proteomics: clinical application, Journal of Physiology and Circulation Research. Michael J. Dunn was recently appointed as Professor of Biomedical Proteomics at University College, Dublin (Ireland), where he is doing proteomics research in the areas of cardiovascular disease, transplantation and neurological disease. Prior to his move to Dublin, he was Professor of Proteomics at the Institute of Psychiatry, King's College London. Dr. Dunn is the current President of the British Society for Proteome Research and the Editor-in-Chief of the journal Proteomics. He is also a founder Council Member of the Human Proteome Organisation (HUPO) and a member of the Executive Committee of the HUPO Brain Proteome Project (BPP).
Editors Overview PART 1: TECHNOLOGIES Pre-analytical issues in clinical proteomic studies Protein separation by 2DE Protein separation : liquid chromatography HPLC in protein discovery IEF analysis of peptides for biomarkers analysis Capillary electrophoresis separations for clinical proteomics Quantitative proteomics using nanoLC with high accuracy mass spectrometry Antibody microarrays for protein and glycan detection Biomarker Identification: The Role of Experimental Design, Statistics, and Data Sharing PART 2: CANCER Applications of stable isotope tagging based quantitive proteomics in cancer research 2-D liquid seperations, protein microarrays and mass spectrometry in comprehensive analysis of PTM and biomarker discovery Development and Use of Reversed-Phase Protein Microarrays for Clinical Applications CDK1 and cancer: usefulness of proteomic approaches in assesment of the molecular mechanisms and efficacy of novel therapeutics PART 3: CARDIOVASCULAR DISEASE Diagnostic markers for monitoring heart transplant rejection The study of microheterogeneity in human plasma proteins: applications to acute myocardial infarction Discovery of biomarkers for cardiovascular diseases Development of biomarker Developfment Pipeline: Search for Myocardial Ischemia Biomarkers Albuminome as a tool for biomarker discovery PART 4: VASCULAR DISEASES Application of Metabolomics to Cardiovascular Biomarker and Pathway Discovery Urinary biomarkers in diabetic nephropathy and other glomerular diseases Pulmonary proteomics Proteomics providing insights into major psychiatric disorders PART 6: BIOMARKERS Redox Proteomics Analysis of Oxidative Modified Brain Proteins in Alzheimer's Disease and Mild Cognitive Impairment: Insights into the Progression of This Dementing Disorder Toxicoproteomics: correlating tissue and serum proteins in liver injuries Biomarkers for renal disease and uraemic toxins HIV and other viral screens PART 6: AUTOANTIBODIES AND SIGNATURE BIOMARKERS Application of Fungal Cyclic Peptides and Metabolites Microarray approaches to autoantibody profiling Identification of tumor antigen-directed autoantibodies PART 7: FUTURE Antibody and Reverse Capture Protein Microarrays Use of Antibody Microarrays in the Analysis of Inflammation, Autoimmunity, Viral Infection, and Cancer Metastases The Future: Translation from Discovery to the Clinic - Roles of HUPO and industry in biomarker discovery